相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Stephan B. Dreyer et al.
GASTROENTEROLOGY (2021)
Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase-Dependent Manner
Lebaron C. Agostini et al.
MOLECULAR CANCER RESEARCH (2021)
CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model
Adam L. Burrack et al.
JOURNAL OF IMMUNOLOGY (2021)
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
Mei Hua Jin et al.
CANCER RESEARCH AND TREATMENT (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
Greta Bagnolini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Developing effective combination therapy for pancreatic cancer: An overview
Aubrey L. Miller et al.
PHARMACOLOGICAL RESEARCH (2020)
Metabolic Alterations in Pancreatic Cancer Progression
Enza Vernucci et al.
CANCERS (2020)
GFAT1/HBP/O-GlcNAcylation Axis Regulates β-Catenin Activity to Promote Pancreatic Cancer Aggressiveness
Chunzeng Jia et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
Ying Ma et al.
GASTROENTEROLOGY (2020)
Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma
Carole Siret et al.
FRONTIERS IN IMMUNOLOGY (2020)
Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer
Shiue-Wei Lai et al.
CELLS (2020)
Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer
Maria Victoria Recouvreux et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes A systematic review and meta-analysis
Yu-Qi Shi et al.
MEDICINE (2020)
FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy
Hortense Chevalier et al.
ONCOLOGIST (2020)
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Elodie Roger et al.
CELLS (2020)
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
Daniel Harrision et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
Neha Sharma et al.
CANCER & METABOLISM (2020)
Synthesis and initial screening of lactate dehydrogenase inhibitor activity of 1,3-benzodioxole derivatives
Dicky Annas et al.
SCIENTIFIC REPORTS (2020)
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer
Rawand Masoud et al.
CELL REPORTS MEDICINE (2020)
Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer
John A. G. Moir et al.
PANCREAS (2020)
Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
Jae Hyup Jung et al.
CANCERS (2020)
KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth
Susanna Raho et al.
NATURE METABOLISM (2020)
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
Francesca Foschini et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
Aubrey L. Miller et al.
CANCER DRUG RESISTANCE (2020)
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
Huimin Lu et al.
BIOSCIENCE REPORTS (2019)
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
Nisha Pillay et al.
CANCER CELL (2019)
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Aesha I. Ali et al.
FRONTIERS IN ONCOLOGY (2019)
Exploiting DNA Replication Stress for Cancer Treatment
Tajinder Ubhi et al.
CANCER RESEARCH (2019)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2019)
Current Status of Immunotherapies for Treating Pancreatic Cancer
Annie A. Wu et al.
CURRENT ONCOLOGY REPORTS (2019)
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
Roheena Z. Panni et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Chemoresistance in Pancreatic Cancer
Siyuan Zeng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
Adam L. Burrack et al.
CELL REPORTS (2019)
Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer
Kun Fan et al.
CANCER MEDICINE (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1
Juan Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Timothy M. Nywening et al.
GUT (2018)
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis
Q. L. Han et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2018)
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy
N. O. Elander et al.
BRITISH JOURNAL OF CANCER (2018)
Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer
Junchen Liu et al.
CANCER RESEARCH (2018)
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Katherine A. Hoadley et al.
CELL (2018)
Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
Polly Gravells et al.
DNA REPAIR (2018)
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M. Haas et al.
EUROPEAN JOURNAL OF CANCER (2018)
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma
Chengyong Yu et al.
FUTURE ONCOLOGY (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior
Shuo Chen et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein
Tsu-Yao Cheng et al.
ONCOGENE (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Tomohiro Kondo et al.
Oncotarget (2018)
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype
Juliana B. Candido et al.
CELL REPORTS (2018)
IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Bhalchandra Mirlekar et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce et al.
FRONTIERS IN IMMUNOLOGY (2018)
Glutamine Deprivation Enhances Acetyl-CoA Carboxylase Inhibitor-induced Death of Human Pancreatic Cancer Cells
Koji Nishi et al.
ANTICANCER RESEARCH (2018)
Prognostic value of pretreatment serum lactate dehydrogenase level in pancreatic cancer patients A meta-analysis of 18 observational studies
Jianxin Gan et al.
MEDICINE (2018)
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Naiara Santana-Codina et al.
NATURE COMMUNICATIONS (2018)
miR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism
De-Hai Wu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
PKM2 is not required for pancreatic ductal adenocarcinoma
Alissandra L. Hillis et al.
CANCER & METABOLISM (2018)
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
Heather L. Kinkead et al.
JCI INSIGHT (2018)
Cancer metabolism: a therapeutic perspective
Ubaldo E. Martinez-Outschoorn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer
Marybeth Anderson et al.
ONCOTARGET (2017)
Hypermutation In Pancreatic Cancer
Jeremy L. Humphris et al.
GASTROENTEROLOGY (2017)
Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells
Hengqiang Zhao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
Guanggai Xia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Jun Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Prasenjit Dey et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine
Toru Aoyama et al.
ONCOLOGY LETTERS (2017)
Endogenous glutamine decrease is associated with pancreatic cancer progression
Cecilia Roux et al.
ONCOTARGET (2017)
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Ru Chen et al.
SCIENTIFIC REPORTS (2017)
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
Takahiro Tsujikawa et al.
CELL REPORTS (2017)
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy SWOG S1115 Study Randomized Clinical Trial
Vincent Chung et al.
JAMA ONCOLOGY (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2017)
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells
Mahsa Zarei et al.
CANCER RESEARCH (2017)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Surendra K. Shukla et al.
CANCER CELL (2017)
Susceptibility of ATM-deficient pancreatic cancer cells to radiation
Michael Ayars et al.
CELL CYCLE (2017)
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Michael J. Pishvaian et al.
BRITISH JOURNAL OF CANCER (2017)
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Stephan B. Dreyer et al.
CLINICAL CANCER RESEARCH (2017)
Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase
Polly Gravells et al.
DNA REPAIR (2017)
Cellular responses to replication stress: Implications in cancer biology and therapy
Hui-Ju Hsieh et al.
DNA REPAIR (2017)
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients
Yuanyuan Xiao et al.
BMC CANCER (2017)
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
Knut J. Labori et al.
ACTA ONCOLOGICA (2016)
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Michele Reni et al.
CLINICAL CANCER RESEARCH (2016)
PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma
Chenggang Li et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells
S. Calabretta et al.
ONCOGENE (2016)
Macrodomains: Structure, Function, Evolution, and Catalytic Activities
Johannes Gregor Matthias Rack et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 85 (2016)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele et al.
CANCER CELL (2016)
Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells
Gang Cheng et al.
CANCER RESEARCH (2016)
PKM2, cancer metabolism, and the road ahead
Talya L. Dayton et al.
EMBO REPORTS (2016)
Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer
Michael I. Koukourakis et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2016)
Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma
Fei Ji et al.
MEDICINE (2016)
PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation
Ninel Azoitei et al.
MOLECULAR CANCER (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells
Su Chii Kong et al.
PANCREAS (2016)
Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome
Goran Hamid Mohammad et al.
PLOS ONE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines
Ilya Kovalenko et al.
PLOS ONE (2016)
Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition
Seung Min Jeong et al.
SCIENTIFIC REPORTS (2016)
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
Shruti Lal et al.
SCIENTIFIC REPORTS (2016)
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
Ingunn M. Stromnes et al.
CANCER CELL (2015)
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Patricia Sancho et al.
CELL METABOLISM (2015)
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Francesca Vena et al.
CLINICAL CANCER RESEARCH (2015)
Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells
Dong Joon Kim et al.
EXPERIMENTAL CELL RESEARCH (2015)
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8+ T Cells
Gustavo J. Martinez et al.
IMMUNITY (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition
Ronan Russell et al.
NATURE COMMUNICATIONS (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
Luca Faloppi et al.
ONCOTARGET (2015)
Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy
Doudou Li et al.
ONCOTARGET (2015)
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
Priyanka Saini et al.
ONCOTARGET (2015)
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
Tasneem Kausar et al.
NEOPLASIA (2015)
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
Congfei Wang et al.
ONCOLOGY REPORTS (2015)
The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer
Hisataka Ogawa et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by β-lapachone
Gaurab Chakrabarti et al.
CANCER & METABOLISM (2015)
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
E. Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2014)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
O. Katopodis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells
Shruti Lal et al.
CANCER RESEARCH (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
Stromal reengineering to treat pancreas cancer
Ingunn M. Stromnes et al.
CARCINOGENESIS (2014)
FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
Jiujie Cui et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway
Zhonghua Wei et al.
FEBS LETTERS (2014)
Re-adapting T cells for cancer therapy: from mouse models to clinical trials
Ingunn M. Stromnes et al.
IMMUNOLOGICAL REVIEWS (2014)
Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium
Everett J. Moding et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
MIR-211 MODULATES GEMCITABINE ACTIVITY THROUGH DOWNREGULATION OF RIBONUCLEOTIDE REDUCTASE AND INHIBITS THE INVASIVE BEHAVIOR OF PANCREATIC CANCER CELLS
Mina Maftouh et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2014)
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
The recognition and removal of cellular poly(ADP-ribose) signals
Eva Barkauskaite et al.
FEBS JOURNAL (2013)
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
Volker Heinemann et al.
GUT (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
DNA Damage Sensing by the ATM and ATR Kinases
Alexandre Marechal et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways
H. Shirai et al.
CELL DEATH & DISEASE (2013)
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Yuriko Saiki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells
Bin Bao et al.
CANCER PREVENTION RESEARCH (2012)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
The Fundamental Role of the p53 Pathway in Tumor Metabolism and Its Implication in Tumor Therapy
Lan Shen et al.
CLINICAL CANCER RESEARCH (2012)
Glucose-6-phosphate dehydrogenase, NADPH, and cell survival
Robert C. Stanton
IUBMB LIFE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
Tyvin A. Rich et al.
ONCOTARGETS AND THERAPY (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
Analysis of cancer metabolism with high-throughput technologies
Aleksandra A. Markovets et al.
BMC BIOINFORMATICS (2011)
Glucose Metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer
Xiaoqun Dong et al.
CANCER (2011)
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase
Nicholas O. Roman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Glucose Metabolism Gene Variants Modulate the Risk of Pancreatic Cancer
Xiaoqun Dong et al.
CANCER PREVENTION RESEARCH (2011)
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2011)
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil
Nobuaki Kurata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
Proteomic Analysis of Pancreatic Ductal Adenocarcinoma Cells Reveals Metabolic Alterations
Weidong Zhou et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Global Profiling of Signaling Networks: Study of Breast Cancer Stem Cells and Potential Regulation
Hongxia Wang et al.
ONCOLOGIST (2011)
Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
Dimitrios Anastasiou et al.
SCIENCE (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
Shahryar E. Mir et al.
CANCER CELL (2010)
Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1
Mayumi Mitsuno et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets
Elizabeth Iorns et al.
PLOS ONE (2009)
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Taro Hitosugi et al.
SCIENCE SIGNALING (2009)
5-fluorouracil: Mechanisms of resistance and reversal strategies
Ning Zhang et al.
MOLECULES (2008)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF
Andreas-Claudius Hoffmann et al.
NEOPLASIA (2008)
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Carolyn E. Clark et al.
CANCER RESEARCH (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular genetics of pancreatic intraepithelial neoplasia
Georg Feldmann et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2007)
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Shin Nakahira et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Daruka Mahadevan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis
Alexandra Giatromanolaki et al.
GYNECOLOGIC ONCOLOGY (2006)
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil
M. Ciaparrone et al.
ONCOLOGY (2006)
Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated
IG Cowell et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas
A Couvelard et al.
HISTOPATHOLOGY (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model
P Büchler et al.
JOURNAL OF SURGICAL RESEARCH (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis
T Masaki et al.
HEPATOLOGY (2003)
Prognostic factors in pancreatic carcinoma - Serum LDH levels predict survival in metastatic disease
F Tas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
分享论文
